×
  • Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Request Free Sample ×

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor
    Hero Background

    Zika Virus Testing Market

    ID: MRFR/LS/4207-HCR
    100 Pages
    Kinjoll Dey
    October 2025

    Zika Virus Testing Market Research Report Information By Tests Include (serological/Zika virus antibody and molecular/nucleic acid amplification), End-Users (Diagnostic units, hospitals, pathology labs), Regions (Asia Pacific, Europe, Americas, and the Middle East and Africa) Forecast till 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Zika Virus Testing Market Infographic
    Purchase Options

    Zika Virus Testing Market Summary

    As per MRFR analysis, the Zika Virus Testing Market Size was estimated at 0.145 USD Billion in 2024. The Zika Virus Testing industry is projected to grow from 0.1547 in 2025 to 0.2965 by 2035, exhibiting a compound annual growth rate (CAGR) of 6.72 during the forecast period 2025 - 2035.

    Key Market Trends & Highlights

    The Zika Virus Testing Market is experiencing notable growth driven by technological advancements and increased public awareness.

    • Technological advancements in testing are enhancing the accuracy and speed of Zika virus diagnostics.
    • North America remains the largest market, while the Asia-Pacific region is emerging as the fastest-growing area for Zika virus testing.
    • The serological segment, focusing on Zika virus antibodies, holds the largest market share, whereas molecular testing is the fastest-growing segment.
    • Rising incidence of Zika virus cases and increased funding for research and development are key drivers propelling market growth.

    Market Size & Forecast

    2024 Market Size 0.145 (USD Billion)
    2035 Market Size 0.2965 (USD Billion)
    CAGR (2025 - 2035) 6.72%

    Major Players

    Abbott Laboratories (US), Roche Diagnostics (CH), Thermo Fisher Scientific (US), Siemens Healthineers (DE), Bio-Rad Laboratories (US), Cepheid (US), Hologic (US), Quidel Corporation (US)

    Zika Virus Testing Market Trends

    The Zika Virus Testing Market is currently experiencing a notable evolution, driven by heightened awareness of vector-borne diseases and advancements in diagnostic technologies. As public health initiatives intensify, the demand for accurate and rapid testing methods appears to be increasing. This shift is likely influenced by the growing recognition of the Zika virus's potential health implications, particularly in pregnant women and newborns. Consequently, stakeholders in the healthcare sector are focusing on developing innovative testing solutions that can provide timely results, thereby facilitating effective disease management and prevention strategies. Moreover, the landscape of the Zika Virus Testing Market is characterized by a diverse array of testing methodologies, including serological tests, molecular diagnostics, and point-of-care testing. These varied approaches suggest a trend towards personalized medicine, where testing can be tailored to individual patient needs. Additionally, collaborations between public health organizations and private entities may enhance the accessibility and affordability of testing services, further driving market growth. As the global health community continues to address the challenges posed by the Zika virus, the market is poised for continued development, reflecting a commitment to safeguarding public health and improving diagnostic capabilities.

    Technological Advancements in Testing

    The Zika Virus Testing Market is witnessing a surge in technological innovations, particularly in molecular diagnostics. These advancements enable faster and more accurate detection of the virus, which is crucial for timely intervention. Enhanced testing platforms, such as real-time PCR and next-generation sequencing, are becoming increasingly prevalent, suggesting a shift towards more sophisticated diagnostic tools.

    Increased Public Awareness

    There appears to be a growing public consciousness regarding the Zika virus and its associated risks. This heightened awareness is likely driving demand for testing services, as individuals seek to understand their health status and mitigate potential risks. Educational campaigns and outreach programs may further contribute to this trend, emphasizing the importance of early detection.

    Collaboration Between Sectors

    The Zika Virus Testing Market is characterized by increasing collaboration between governmental health agencies and private sector entities. Such partnerships may enhance the development and distribution of testing solutions, ensuring that they are both accessible and affordable. This collaborative approach could lead to improved public health outcomes and a more robust response to Zika virus outbreaks.

    Zika Virus Testing Market Drivers

    Regulatory Support and Guidelines

    Regulatory support and guidelines play a crucial role in shaping the Zika Virus Testing Market. Governments and health organizations are actively developing and updating testing protocols to ensure accurate and timely diagnosis of Zika virus infections. This regulatory framework not only enhances the credibility of testing methods but also encourages manufacturers to innovate and improve their testing solutions. As a result, the Zika Virus Testing Market is likely to witness a proliferation of advanced testing kits and methodologies that comply with these regulations. Moreover, the establishment of clear guidelines may facilitate faster approval processes for new testing technologies, further stimulating market growth.

    Rising Incidence of Zika Virus Cases

    The increasing incidence of Zika virus cases is a primary driver for the Zika Virus Testing Market. Reports indicate that the number of reported cases has seen fluctuations, with certain regions experiencing outbreaks. This rise in cases necessitates enhanced testing capabilities to monitor and control the spread of the virus. As health authorities prioritize public health, the demand for reliable testing solutions is expected to surge. The Zika Virus Testing Market is likely to benefit from this trend, as healthcare providers seek to implement effective diagnostic measures. Furthermore, the need for timely detection and response to outbreaks may lead to increased investments in testing technologies, thereby expanding the market.

    Technological Innovations in Diagnostic Tools

    Technological innovations in diagnostic tools are significantly influencing the Zika Virus Testing Market. The advent of advanced molecular techniques, such as PCR and next-generation sequencing, has revolutionized the way Zika virus infections are detected. These innovations enable rapid and accurate testing, which is essential for effective disease management. The market is witnessing a shift towards more sophisticated testing solutions that offer higher sensitivity and specificity. As healthcare providers increasingly adopt these technologies, the Zika Virus Testing Market is expected to expand. Furthermore, the integration of digital health solutions, such as mobile applications for test results, may enhance patient engagement and streamline testing processes.

    Increased Funding for Research and Development

    Increased funding for research and development is a significant driver of the Zika Virus Testing Market. Governments, non-profit organizations, and private entities are allocating resources to develop new testing methodologies and improve existing ones. This financial support is crucial for fostering innovation and ensuring that testing solutions keep pace with the evolving nature of the virus. As research initiatives gain momentum, the Zika Virus Testing Market is likely to see the introduction of novel diagnostic tools that enhance detection capabilities. Additionally, this influx of funding may lead to collaborative efforts between academic institutions and industry players, further propelling market growth.

    Growing Demand for Preventive Healthcare Measures

    The growing demand for preventive healthcare measures is shaping the Zika Virus Testing Market. As awareness of vector-borne diseases increases, individuals and communities are seeking proactive solutions to mitigate risks associated with Zika virus infections. This trend is driving the need for widespread testing, particularly in regions prone to outbreaks. Healthcare providers are responding by offering comprehensive testing services as part of preventive health strategies. Consequently, the Zika Virus Testing Market is likely to experience growth as more individuals opt for testing to ensure early detection and management of potential infections. This shift towards preventive healthcare may also encourage the development of educational campaigns to inform the public about the importance of testing.

    Market Segment Insights

    By Test Type: Serological/Zika virus antibody (Largest) vs. Molecular/Nucleic acid amplification (Fastest-Growing)

    In the Zika Virus Testing Market, serological tests, which detect Zika virus antibodies in the blood, account for a significant portion of the market share. This segment's robustness is attributed to its reliance on well-established methodologies and widespread usability. The convenience of testing for antibodies rather than detecting the virus itself has made this segment the largest within the market, as clinics and laboratories prefer these tests for their reliability and straightforward implementation. On the other hand, molecular tests, particularly nucleic acid amplification tests (NAAT), are emerging rapidly due to advancements in technology and their ability to provide quicker results. This segment is becoming increasingly pivotal as the demand for timely and accurate diagnostics continues to rise. Factors fueling growth in molecular testing include rising infectious disease outbreaks, increased public health awareness, and ongoing technological innovations that enhance testing accuracy and speed.

    Test Method: Serological/Zika virus antibody (Dominant) vs. Molecular/Nucleic acid amplification (Emerging)

    The serological test for Zika virus antibodies remains the dominant methodology in the market, largely due to its established presence in diagnostic laboratories and a broader acceptance among healthcare providers. This test is capable of identifying past infections, which is highly valuable for public health monitoring and epidemiological studies. Conversely, molecular tests, such as nucleic acid amplification, represent an emerging segment in the Zika virus testing landscape. These tests are favored for their sensitivity and specificity, enabling rapid detection of the virus in patients, particularly during the acute phase of infection. As technology continues to evolve, the molecular segment is expected to capture a growing share of the market, driven by the need for faster diagnostics in healthcare settings.

    By End-User: Diagnostic Units (Largest) vs. Pathology Labs (Fastest-Growing)

    In the Zika Virus Testing Market, the end-user segment includes diagnostic units, hospitals, and pathology labs. Diagnostic units hold a significant proportion of the market share, primarily due to their essential role in rapid testing and accurate diagnosis of Zika virus infections. Hospitals also play a pivotal role, accommodating a large number of patients and providing necessary testing services. However, pathology labs are growing in prominence as they enhance their capabilities and expand service offerings, catering to an increasing demand for specialized testing.

    Zika Virus Testing Market: Diagnostic Units (Dominant) vs. Pathology Labs (Emerging)

    Diagnostic units are currently the dominant force within the Zika Virus Testing Market, regarded for their efficiency and essential function in diagnosing viral infections quickly. These units streamline testing processes, often employing advanced technologies that facilitate timely results. In contrast, pathology labs represent an emerging segment within this market, rapidly evolving to meet the growing need for comprehensive testing services. These labs enhance their testing capabilities and introduce innovative techniques, positioning themselves as key players in Zika diagnostics. As awareness and prevalence of Zika virus rise, both segments will see shifts in demand, but diagnostic units are currently better positioned due to their established infrastructure.

    Get more detailed insights about Zika Virus Testing Market

    Key Companies in the Zika Virus Testing Market market include

    Industry Developments

    The FDA has given the commercial Altona Diagnostics RealStar ZIKV RT-PCR test kit (Altona PCR) emergency use authorization. The goal of this study was to compare the Altona PCR to the CDC-designed dual-target ZIKV RT-PCR reference assay (reference PCR) and to characterize the demographics of ZIKV RT-PCR patients in Ontario, Canada. The Altona PCR and the reference PCR were used to test a significant number of clinical specimens for ZIKV. Positive and ambiguous specimens were subjected to ZIKV NS5 gene PCR and Sanger sequencing.

    Luminex Corporation is a biotechnology firm that creates, produces, and distributes patented biological diagnostic methods and products. Flow cytometers, cellular analysis devices, a platform for monitoring genes and proteins, and other diagnostics and research tools are among the company's products. Clinical diagnostics, pharmaceutical drug development, biomedical research, genomic and proteomic research, and food safety are among the markets served by Luminex.

    Eminent Players and Industry Advancements

    Prominent companies affiliated with the Zika virus testing market comprise Luminex Corporation, ARUP Laboratories, Roche Molecular Systems, Hologic, and Siemens Healthcare Diagnostics. To create efficient treatments and vaccines, advanced animal models are required. An improved comprehension of immunological protection correlates is also needed to protect ourselves from this disease.

    Nowadays, the Zika virus is detected in view of clinical manifestations. Molecular detection and serological devices also play a major role. As the separation of this virus is difficult; LFAs, NASBA, and LAMP are used to detect the virus and ascertain the cause of the fever. These novel techniques have assisted in accurate & fast diagnosis. With the clinical symptoms of Zika not being pathognomic, the presence of this virus can be established only when it is separated and examined.

    Few among many clinical symptoms of this disease are myalgia, headache, fever, maculopapular rashes, and arthralgia. Only upon further diagnosis and confirmation, are the treatments recommended to patients. Sometimes, similar symptoms can be mistaken for other illnesses. Thus, it’s best to go to the doctors and have it ruled in/out.

    Key Players:

    Zika Virus Testing Market Industry Developments

    • Q2 2024: FDA Authorizes Emergency Use of New Zika Virus RT-PCR Test Developed by BioGenDx The FDA granted Emergency Use Authorization to BioGenDx for its new rapid RT-PCR test for Zika virus, enabling faster detection during ongoing outbreaks in the Americas.
    • Q1 2024: Roche Launches Next-Generation Zika Virus Diagnostic Test in Latin America Roche announced the commercial launch of its next-generation Zika virus molecular diagnostic test, designed for high-throughput laboratories, in Brazil and other Latin American countries.
    • Q3 2024: Siemens Healthineers Partners with Brazilian Ministry of Health for Zika Virus Testing Market Rollout Siemens Healthineers signed a partnership agreement with Brazil's Ministry of Health to supply advanced Zika virus testing platforms to public health laboratories amid rising case numbers.
    • Q2 2024: Thermo Fisher Scientific Expands Zika Virus Test Production Capacity in Singapore Facility Thermo Fisher Scientific announced the expansion of its Singapore manufacturing facility to increase production of Zika virus molecular diagnostic kits, responding to heightened demand in Southeast Asia.
    • Q4 2024: Abbott Receives CE Mark for Multiplex Zika, Dengue, and Chikungunya Test Abbott Laboratories received CE Mark approval for its multiplex molecular assay that simultaneously detects Zika, dengue, and chikungunya viruses, enabling broader deployment in European and global markets.
    • Q1 2025: QuidelOrtho Acquires Zika Rapid Test Startup ViraSure for $120 Million QuidelOrtho completed the acquisition of ViraSure, a startup specializing in rapid Zika virus diagnostic tests, to strengthen its infectious disease testing portfolio.
    • Q2 2025: Bio-Rad Laboratories Launches Point-of-Care Zika Virus Antibody Test in Africa Bio-Rad Laboratories launched a new point-of-care Zika virus IgM/IgG antibody test, targeting rapid diagnosis in remote and resource-limited African regions.
    • Q3 2024: GenMark Diagnostics Announces $50 Million Funding Round to Accelerate Zika Test Development GenMark Diagnostics disclosed in an SEC filing that it raised $50 million in new funding to accelerate the development and regulatory submission of its next-generation Zika virus diagnostic platform.
    • Q2 2024: Hologic Wins Major Zika Virus Testing Market Contract from Pan American Health Organization Hologic secured a multi-year contract with the Pan American Health Organization to supply Zika virus molecular testing kits to public health labs across Central and South America.
    • Q4 2024: CDC Updates Zika Virus Testing Market Guidelines and Approves New Diagnostic Panel The U.S. Centers for Disease Control and Prevention (CDC) updated its Zika virus testing guidelines and approved a new diagnostic panel for use in state and local public health laboratories.
    • Q1 2025: Siemens Healthineers Appoints New Head of Zika Virus Diagnostics Division Siemens Healthineers announced the appointment of Dr. Maria Alvarez as the new head of its Zika virus diagnostics division, aiming to drive innovation and global market expansion.
    • Q2 2025: Roche Receives ANVISA Approval for Zika Virus PCR Test in Brazil Roche received regulatory approval from Brazil's ANVISA for its Zika virus PCR test, enabling broader clinical use in the country amid ongoing public health concerns.

    Future Outlook

    Zika Virus Testing Market Future Outlook

    The Zika Virus Testing Market is projected to grow at a 6.72% CAGR from 2024 to 2035, driven by technological advancements, increased awareness, and rising incidences of Zika virus infections.

    New opportunities lie in:

    • Development of rapid, point-of-care testing kits for remote areas.
    • Integration of AI-driven analytics for enhanced diagnostic accuracy.
    • Expansion of telehealth services for Zika virus testing consultations.

    By 2035, the Zika Virus Testing Market is expected to be robust, driven by innovation and increased demand.

    Market Segmentation

    Zika Virus Testing Market End-User Outlook

    • Diagnostic units
    • Hospitals
    • Pathology labs

    Zika Virus Testing Market Test Type Outlook

    • Serological/Zika virus antibody
    • Molecular/Nucleic acid amplification

    Report Scope

    MARKET SIZE 20240.145(USD Billion)
    MARKET SIZE 20250.1547(USD Billion)
    MARKET SIZE 20350.2965(USD Billion)
    COMPOUND ANNUAL GROWTH RATE (CAGR)6.72% (2024 - 2035)
    REPORT COVERAGERevenue Forecast, Competitive Landscape, Growth Factors, and Trends
    BASE YEAR2024
    Market Forecast Period2025 - 2035
    Historical Data2019 - 2024
    Market Forecast UnitsUSD Billion
    Key Companies ProfiledMarket analysis in progress
    Segments CoveredMarket segmentation analysis in progress
    Key Market OpportunitiesAdvancements in molecular diagnostics enhance accuracy and speed in the Zika Virus Testing Market.
    Key Market DynamicsRising demand for rapid Zika virus testing drives innovation and competition among diagnostic manufacturers.
    Countries CoveredNorth America, Europe, APAC, South America, MEA

    Market Highlights

    Author
    Kinjoll Dey
    Research Analyst Level I

    He is an extremely curious individual currently working in Healthcare and Medical Devices Domain. Kinjoll is comfortably versed in data centric research backed by healthcare educational background. He leverages extensive data mining and analytics tools such as Primary and Secondary Research, Statistical Analysis, Machine Learning, Data Modelling. His key role also involves Technical Sales Support, Client Interaction and Project management within the Healthcare team. Lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.

    Leave a Comment

    Download Free Sample

    Kindly complete the form below to receive a free sample of this Report

    Compare Licence

    ×
    Features License Type
    Single User Multiuser License Enterprise User
    Price $4,950 $5,950 $7,250
    Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
    Free Customization
    Direct Access to Analyst
    Deliverable Format
    Platform Access
    Discount on Next Purchase 10% 15% 15%
    Printable Versions